Devine, P. J., Ekert, J., Kopec, A. K., Stresser, D. M., Ramsden, D., Szilagyi, J., Hewitt, P., Hardwick, R. N., Laing, S., Van Vleet, T. R., Moalli, M., & Bajaj, P. (2025). Pharmaceutical industry perspective on the utility of animal cell-based microphysiological systems to support human drug development. ALTEX, 10.14573/altex.2407122.

Celauro, E., Saleh, A. F., Mahalingaiah, P. K., Mohamet, L., David, R., & Nitsch, R. (2025). Exploring the synergy of CRISPR and microphysiological systems. ALTEX - Alternatives to Animal Experimentation. https://doi.org/10.14573/altex.2403251

Celauro, E., Saleh, A. F., Mahalingaiah, P. K., Mohamet, L., David, R., & Nitsch, R. (2025). Exploring the synergy of CRISPR and microphysiological systems. ALTEX – Alternatives to Animal Experimentation. 

Devine, P. J., Guha, M., Ekert, J. E., Kopec, A. K., Gosset, J. R., Freag, M. S., Wagoner, M. P., Hewitt, P., Harris, K., Lemmens, M., Sadrieh, N., et al. (2025). Considerations from the pharmaceutical industry (IQ MPS Affiliate) workshop on animal microphysiological systems and 3Rs in drug development. ALTEX – Alternatives to Animal Experimentation. 

Candarlioglu, P. L., Delsing, L., Gauthier, L., Lewis, L., Papadopoulos, G., Freag, M., Chan, T. S., Homan, K. A., Fellows, M. D., Pointon, A. (2024) Application of Microphysiological Systems for Nonclinical Evaluation of Cell Therapies. ALTEX Alternatives to animal experimentation

Baker, T. K., Van Vleet, T. R., Mahalingaiah, P. K., Grandhi, T. S. P., Evers, R., Ekert, J., Gosset, J. R., Chacko, S. A., & Kopec, A. K. (2024). The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary. Drug metabolism and disposition: the biological fate of chemicals, 52(3), 198–209.

Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., ... & Homan, K. A. (2023). Towards in vitro models for reducing or replacing the use of animals in drug testing. Nature Biomedical Engineering, 1-6.   

Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., ... & Hardwick, R. N. (2023). Considerations from an international regulatory and pharmaceutical industry (IQ MPS Affiliate) workshop on the standardization of complex in vitro models in drug development. Advanced Biology, 2300131.

Irrechukwu, O., Yeager, R., David, R. ., Ekert, J., Saravanakumar, A. and Choi, C. K. (2023) Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges. ALTEX - Alternatives to animal experimentation..

Wang, X., Kopec, A., Collinge, M., David, R., Grant, C., Hardwick, R., Navratil, A., Patel, N., Rowan, W. and Marshall, N. (2022) Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations. ALTEX - Alternatives to animal experimentation.

Ramsden, D., Belair, D. G., Agarwal, S., Andersson, P., Humphreys, S., Dalmas, D. A., ... & Cichocki, J. A. (2022) Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics. ALTEX-Alternatives to animal experimentation.

Baran, S. W., Brown, P. C., Baudy, A. R., Fitzpatrick, S. C., Frantz, C., Fullerton, A., … Ekert, J. E. (2022). Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX - Alternatives to Animal Experimentation, 39(2), 297–314

Pointon, A., Maher, J., Davis, M., Baker, T. K., Cichocki, J., Ramsden, D., ... & Gintant, G. A. (2021). Cardiovascular Microphysiological Systems (CVMPS) for Safety Studies-A Pharma Perspective. Lab on a Chip.

Peters, M., Choy, A., Pin, C., Leishman, D., Moisan. A., Ewart, L., Guzzie-Peck, P., Sura, R., Keller, D., Scott, C., Kolaja, L. (2019) Developing in vitro Assays to Transform Gastrointestinal Safety Assessment: Potential for Microphysiological Systems. Lab on Chip.

Fabre, K., Berridge, B., Proctor, W., Ralston, S., Will, Y., Baran, SW., Yoder, G., Van Vleet, T. (2019) An Introduction to the Characterization and Use of Microphysiological Systems (MPS) in Pharmaceutical Safety and ADME Applications. Lab on a Chip.

Peterson, N., Mahalingaiah, P. K., Fullerton, A., Di Piazza, M. (2019) Application of 3D Cultures and Microphysiological Systems in Biopharmaceutical Research and Development. Lab on a Chip.

Philips, J.A., Grandhi, T.S.P., Davis, M., Gautier, J.C., Hariparsad, N., Keller, D., Sura, R., Van Vleet, T. (2019) A Pharmaceutical Industry Perspective on Microphysiological Kidney Systems for Evaluation of New Therapies. Lab on a Chip.

Fowler, S., Chen, W.L.K., Duigan, D., Gupta, A., Hariparsad, N., Kenny, J., Lai, G., Liras, J., Phillips, J., Gan, J. (2019) Microphysiological Systems for ADME-Related Applications: Current Status and Recommendations for System Development and Characterisation. Lab on Chip.

Baudy, A.R., Otieno, M.A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T.R., Proctor, W.R., (2019) Liver Microphysiological Systems Development Guidelines for Safety Risk Assessment in the Pharmaceutical Industry. Lab on a Chip.

Hardwick, R.N., Betts, C.J., Whritenour, J., Sura, R., Thamsen, M., Kaufman E., Fabre K., (2019) Drug-Induced Skin Toxicity: Gaps in Preclinical Testing Cascade as Opportunities for Complex In Vitro Models and Assay. Lab on a Chip.

Ainslie, G. R., Davis, M., Ewart, L., Lieberman, L. A., Rowlands, D. J., Thorley, A. J., Yoder, G., Ryan, A. M. (2019). Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective. Lab on a Chip.

Ewart, L., Fabre, K., Chakilam, A., Dragan, Y., Duignan, D. B., Eswaraka, J., Gan, J., Guzzie-Peck, P., Otieno, M., Jeong, C. G., Keller, D. A., de Morais, S. M., Phillips, J. A., Proctor, W., Sura, R., Van Vleet, T., Watson, D., Will, Y., Tagle, D., & Berridge, B. (2017). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Experimental biology and medicine (Maywood, N.J.), 242(16), 1579–1585.